Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O1XU
|
||||
| Former ID |
DIB002183
|
||||
| Drug Name |
XR-3005
|
||||
| Indication | Colorectal cancer [ICD9: 153, 154; ICD10:C18-C21] | Terminated | [1] | ||
| Company |
Xenova Group plc
|
||||
| Target and Pathway | |||||
| Target(s) | Protein farnesyltransferase beta subunit | Target Info | Modulator | [2] | |
| KEGG Pathway | Terpenoid backbone biosynthesis | ||||
| Biosynthesis of antibiotics | |||||
| NetPath Pathway | TSH Signaling Pathway | ||||
| Reactome | Inactivation, recovery and regulation of the phototransduction cascade | ||||
| WikiPathways | Visual phototransduction | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005580) | ||||
| REF 2 | US patent application no. 2005,0227,929, Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.